8622 — Huakang Biomedical Holdings Co Income Statement
0.000.00%
Last trade - 00:00- HK$180.17m
- HK$142.57m
- CNY25.36m
Annual income statement for Huakang Biomedical Holdings Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 22 | 26.1 | 25.3 | 24.6 | 25.4 |
| Cost of Revenue | |||||
| Gross Profit | 14.7 | 16.5 | 16.9 | 15.9 | 17.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 33.3 | 29.9 | 28.3 | 30.4 | 29.4 |
| Operating Profit | -11.3 | -3.8 | -2.95 | -5.73 | -4.07 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -11.4 | -3.9 | -3.01 | -5.78 | -4.16 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -11.6 | -4.22 | -3.08 | -5.78 | -4.16 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -11.6 | -4.22 | -3.08 | -5.78 | -4.16 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11.6 | -4.22 | -3.08 | -5.78 | -4.16 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.025 | -0.011 | -0.008 | -0.014 | -0.009 |